Top-News
Pharmazeutika Frankreich

Nicox News

Aktie
WKN:  A143G8 ISIN:  FR0013018124 US-Symbol:  NICXF
0,2155 €
-0,0145 €
-6,30%
14.06.24 21:50:23
Handeln Depot/Watchlist
Aktienanzahl *
50,17 Mio.
Marktkapitalisierung *
12,07 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 20.09.2023

Nicox News

24.05.24 - GlobeNewswire
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28 th , 2024 May 24, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext ...
06.05.24 - GlobeNewswire
Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
Press Release Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary ...
24.04.24 - GlobeNewswire
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent April 24, 2024 – release at 07:30 ...
22.04.24 - GlobeNewswire
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024 ...
09.04.24 - GlobeNewswire
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting April 9, 2024 – release at 17:30 CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, ...
22.03.24 - GlobeNewswire
Nicox's Shareholder Letter
Dear Shareholder,
20.03.24 - GlobeNewswire
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
Press Release
13.03.24 - GlobeNewswire
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
Press Release
05.03.24 - GlobeNewswire
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
Press Release
28.02.24 - GlobeNewswire
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
Press Release
28.02.24 - GlobeNewswire
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
Press Release
08.02.24 - GlobeNewswire
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
Press Release Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan €3 million upfront payment and a total of a further potential €27.5 ...
06.02.24 - GlobeNewswire
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
Press Release Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 February 6, 2024 – release at ...
31.01.24 - GlobeNewswire
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
Press Release Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA ® January 31, 2024 – release ...
25.01.24 - GlobeNewswire
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomized Net revenue €1.3 million for fourth ...
18.12.23 - GlobeNewswire
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
Press Release Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma December 18, 2023 – release at 7:30 am CET Sophia Antipolis, ...
14.12.23 - GlobeNewswire
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
Press Release Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan December ...
20.10.23 - GlobeNewswire
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
Press Release Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones  Third quarter 2023 U.S. prescriptions for VYZULTA ® ...
19.07.23 - GlobeNewswire
Nicox Provides Second Quarter 2023 Financial and Business Highlights
Press Release Nicox Provides Second Quarter 2023 Financial and Business Highlights Net revenue 1 of € 0.9 million for the second quarter of 2023 Cash position of € 19 .0 million ...
10.07.23 - GlobeNewswire
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
Press Release Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million NCX 470 therapeutic profile positively received a m ong U.S. eye care ...

Newssuche

Videos

newspaper
13.06.24 -3,86%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »